Military Medical Academy - MHAT - Sofia
Welcome,         Profile    Billing    Logout  
 12 Trials 
52 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Chong, Benjamin F
NCT05531565 / 2020-000727-40: A Study to Assess the Efficacy and Safety of BIIB059 (Litifilimab) in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy

Recruiting
2/3
474
Europe, Canada, Japan, US, RoW
BIIB059 (litifilimab), litifilimab, Placebo
Biogen, Biogen Idec Research Limited
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
10/26
12/27
NCT01510067: Prevalence and Clinical Severity of Cutaneous Lupus Erythematosus

Recruiting
N/A
700
US
University of Pennsylvania
Cutaneous Lupus Erythematosus (CLE)
01/25
01/25
NCT01266915: Cutaneous Lupus Registry

Recruiting
N/A
500
US
University of Texas Southwestern Medical Center
Lupus Erythematosus
12/25
12/25
Najam, Sabeen
BE-EARLY, NCT06411249: A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)

Recruiting
4
350
Europe, Japan, US, RoW
Belimumab (GSK1550188), BEL (BENLYSTA)
GlaxoSmithKline
Systemic Lupus Erythematosus
04/27
05/29
RA-BRANCH, NCT04086745: A Study of Baricitinib in Participants With Rheumatoid Arthritis

Recruiting
4
1300
US
Baricitinib, LY3009104, TNF Inhibitor, Etanercept, Adalimumab
Eli Lilly and Company, Incyte Corporation
Rheumatoid Arthritis
12/24
02/26
NCT04314531: Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)

Active, not recruiting
3
292
Europe, Japan, US, RoW
TILD, matching placebo injections
Sun Pharmaceutical Industries Limited
Active Psoriatic Arthritis
09/24
12/24
NCT04314544: Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)

Recruiting
3
472
Europe, Canada, US, RoW
TILD, matching placebo injections
Sun Pharmaceutical Industries Limited
Active Psoriatic Arthritis
06/24
03/25
TOPAZ-1, NCT04895241 / 2020-005775-12: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Checkmark Trial initiation of TOPAZ-1 trial in lupus
Jun 2021 - Jun 2021: Trial initiation of TOPAZ-1 trial in lupus
Recruiting
3
540
Europe, US, RoW
Litifilimab, BIIB059, Placebo
Biogen
Lupus Erythematosus, Systemic
03/25
09/25
NCT04991116: Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis

Recruiting
3
650
Europe, Japan, US, RoW
TILD sub-cutaneous (SC) injection
Sun Pharmaceutical Industries Limited
Psoriatic Arthritis
09/25
01/26
NCT06104124: A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

Recruiting
3
510
Japan, US, RoW
Dazodalibep, VIB 4920, MEDI 4920, Placebo
Amgen
Sjogren's Syndrome
07/26
07/26
SIRIUS-SLE 1, NCT05639114 / 2022-002691-36: Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus

Recruiting
3
406
Europe, Canada, Japan, US, RoW
Ianalumab, VAY736, Placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Systemic Lupus Erythematosus
01/27
01/29
RESOLUTION-1, NCT05516758: A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis

Active, not recruiting
2
491
Europe, Canada, Japan, US, RoW
Peresolimab, Placebo
Eli Lilly and Company
Rheumatoid Arthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases, Connective Tissue Diseases, Autoimmune Diseases, Immune System Diseases
11/23
01/25
NCT03631225: The Effect of Guided Care With Vectra Compared to Treatment as Usual in Patients With Rheumatoid Arthritis

Recruiting
N/A
1500
US
Vectra
Sequenom, Inc., Laboratory Corporation of America
Rheumatoid Arthritis (RA)
09/25
09/25
Lazaro, Maria Alicia
NCT05848258: An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis

Recruiting
2
380
Europe, US, RoW
LY3871801, Placebo
Eli Lilly and Company, Rigel Pharmaceuticals
Rheumatoid Arthritis
02/26
07/26
WILLOW, NCT05162586 / 2021-004648-27: The Study With M5049 in SLE and CLE (SCLE and/or DLE)

Active, not recruiting
2
532
Europe, Japan, US, RoW
Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Systemic Lupus Erythematosus
07/24
08/24
WILLOW LTE, NCT05540327 / 2022-000239-21: The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE

Recruiting
2
532
Europe, Japan, US, RoW
M5049 low dose, Enpatoran, M5049 medium dose, M5049 high dose, Placebo, M5049 very high dose
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Merck Healthcare KGaA
Systemic Lupus Erythematosus
04/25
04/25
Zamora, Jose Luis Velasco
BE-EARLY, NCT06411249: A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)

Recruiting
4
350
Europe, Japan, US, RoW
Belimumab (GSK1550188), BEL (BENLYSTA)
GlaxoSmithKline
Systemic Lupus Erythematosus
04/27
05/29
TOPAZ-2, NCT04961567 / 2020-005776-35: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Recruiting
3
540
Europe, Canada, Japan, US, RoW
Litifilimab, BIIB059, Placebo
Biogen
Lupus Erythematosus, Systemic
09/25
03/26
NCT05531565 / 2020-000727-40: A Study to Assess the Efficacy and Safety of BIIB059 (Litifilimab) in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy

Recruiting
2/3
474
Europe, Canada, Japan, US, RoW
BIIB059 (litifilimab), litifilimab, Placebo
Biogen, Biogen Idec Research Limited
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
10/26
12/27
Rodgers, Timothy
TAK-279-3002, NCT06108544: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

Recruiting
3
1000
Europe, Canada, US
TAK-279, Placebo, Apremilast
Takeda
Plaque Psoriasis
07/25
06/26
NCT05531565 / 2020-000727-40: A Study to Assess the Efficacy and Safety of BIIB059 (Litifilimab) in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy

Recruiting
2/3
474
Europe, Canada, Japan, US, RoW
BIIB059 (litifilimab), litifilimab, Placebo
Biogen, Biogen Idec Research Limited
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
10/26
12/27
NCT06436183: A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis

Recruiting
2
60
Canada, US
Camoteskimab, APL-9109, AVTX-007, CERC-007, AEVI-007, MEDI2338, Placebo
Apollo Therapeutics Ltd
Atopic Dermatitis, Atopic, Dermatitis, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis, Eczema, Atopic
02/25
06/25
NCT06046729: A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Recruiting
2
350
Europe, Canada, US, RoW
Eltrekibart, LY3041658, Placebo
Eli Lilly and Company
Hidradenitis Suppurativa
08/25
07/26
TARGET-DERM, NCT03661866: A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

Recruiting
N/A
15000
Europe, Canada, US
Target PharmaSolutions, Inc.
Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Spontaneous Urticaria
12/50
12/50
Basu, Dhiman
BE-EARLY, NCT06411249: A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)

Recruiting
4
350
Europe, Japan, US, RoW
Belimumab (GSK1550188), BEL (BENLYSTA)
GlaxoSmithKline
Systemic Lupus Erythematosus
04/27
05/29
SELUNE, NCT04181762 / 2019-003211-57: Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis

Terminated
3
275
Europe, Canada, Japan, US, RoW
secukinumab, AIN457
Novartis Pharmaceuticals
Lupus Nephritis
09/23
09/23
RESET-RA, NCT04539964: Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis

Active, not recruiting
3
250
US
Implant Procedure, Surgical placement of vagus nerve stimulator inside the neck, Conventional Synthetic DMARD, Background therapy with conventional synthetic DMARD, Active stimulation, Non-active stimulation
SetPoint Medical Corporation
Rheumatoid Arthritis
05/24
10/27
NCT04314531: Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)

Active, not recruiting
3
292
Europe, Japan, US, RoW
TILD, matching placebo injections
Sun Pharmaceutical Industries Limited
Active Psoriatic Arthritis
09/24
12/24
NCT04314544: Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)

Recruiting
3
472
Europe, Canada, US, RoW
TILD, matching placebo injections
Sun Pharmaceutical Industries Limited
Active Psoriatic Arthritis
06/24
03/25
TOPAZ-1, NCT04895241 / 2020-005775-12: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Checkmark Trial initiation of TOPAZ-1 trial in lupus
Jun 2021 - Jun 2021: Trial initiation of TOPAZ-1 trial in lupus
Recruiting
3
540
Europe, US, RoW
Litifilimab, BIIB059, Placebo
Biogen
Lupus Erythematosus, Systemic
03/25
09/25
NEPTUNUS-1, NCT05350072 / 2020-005661-14: Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

Active, not recruiting
3
276
Europe, US, RoW
VAY736, Placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Sjogren Syndrome
03/26
03/28
RA-PROPR, NCT04692493: RA-PRO PRAGMATIC TRIAL

Recruiting
3
924
Canada, US
targeted synthetic DMARD class, non-TNFi-biologic class
University of Alabama at Birmingham, Patient-Centered Outcomes Research Institute
Rheumatoid Arthritis
09/26
12/28
NCT05531565 / 2020-000727-40: A Study to Assess the Efficacy and Safety of BIIB059 (Litifilimab) in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy

Recruiting
2/3
474
Europe, Canada, Japan, US, RoW
BIIB059 (litifilimab), litifilimab, Placebo
Biogen, Biogen Idec Research Limited
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
10/26
12/27
WILLOW, NCT05162586 / 2021-004648-27: The Study With M5049 in SLE and CLE (SCLE and/or DLE)

Active, not recruiting
2
532
Europe, Japan, US, RoW
Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Systemic Lupus Erythematosus
07/24
08/24
NCT05781750: A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE)

Recruiting
2
279
Europe, US, RoW
zetomipzomib, KZR-616, placebo, matching placebo
Kezar Life Sciences, Inc.
Lupus Nephritis
05/26
07/26
Brionez, Tamar
COVER-CoAd, NCT05543642: The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients

Active, not recruiting
4
129
US
Hepatitis A vaccine, Havrix, Diphtheria, pertussis, and tetanus booster vaccine, Boostrix
Oregon Health and Science University
Rheumatic Diseases
01/25
12/25
SERENITY CM, NCT05614648: Sciatica Epidural Radiculopathy Experimental New Interventional TherapY Clonidine Micropellet

Terminated
3
17
US
Clonidine Micropellets, Tuohy epidural needle
Sollis Therapeutics, Inc.
Lumbosacral Radiculopathy
03/24
03/24
GCAptAIN, NCT04930094: Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)

Active, not recruiting
3
354
Europe, Canada, US, RoW
Secukinumab 300 mg, AIN457, Placebo, Placebo Comparator, Secukinumab 150 mg
Novartis Pharmaceuticals
Giant Cell Arteritis (GCA)
04/25
07/27
TOPAZ-1, NCT04895241 / 2020-005775-12: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Checkmark Trial initiation of TOPAZ-1 trial in lupus
Jun 2021 - Jun 2021: Trial initiation of TOPAZ-1 trial in lupus
Recruiting
3
540
Europe, US, RoW
Litifilimab, BIIB059, Placebo
Biogen
Lupus Erythematosus, Systemic
03/25
09/25
REPLENISH, NCT05767034: Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)

Recruiting
3
360
Europe, Canada, Japan, US, RoW
Secukinumab 300 mg, AIN457, Secukinumab 150 mg, Placebo to secukinumab
Novartis Pharmaceuticals
Polymyalgia Rheumatica
09/25
02/26
NEPTUNUS-2, NCT05349214 / 2021-005687-22: Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

Recruiting
3
489
Europe, Canada, Japan, US, RoW
VAY736, Placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Sjogren Syndrome
03/26
03/28
NEPTUNUS-Ext, NCT05985915: A Randomized, Double-blind 2-arm NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

Recruiting
3
600
Europe, Canada, Japan, US, RoW
Ianalumab (VAY736), Placebo
Novartis Pharmaceuticals
Sjogrens Syndrome
08/28
07/30
NCT05690204: Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001.

Recruiting
2
80
US
SAP001, Xanthine Oxidase Inhibitor, Colchicine
Shanton Pharma Co., Ltd.
Gout
12/24
01/25
Testa, Gladys Alicia
TOPAZ-2, NCT04961567 / 2020-005776-35: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Recruiting
3
540
Europe, Canada, Japan, US, RoW
Litifilimab, BIIB059, Placebo
Biogen
Lupus Erythematosus, Systemic
09/25
03/26
NCT05531565 / 2020-000727-40: A Study to Assess the Efficacy and Safety of BIIB059 (Litifilimab) in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy

Recruiting
2/3
474
Europe, Canada, Japan, US, RoW
BIIB059 (litifilimab), litifilimab, Placebo
Biogen, Biogen Idec Research Limited
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
10/26
12/27
WILLOW, NCT05162586 / 2021-004648-27: The Study With M5049 in SLE and CLE (SCLE and/or DLE)

Active, not recruiting
2
532
Europe, Japan, US, RoW
Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Systemic Lupus Erythematosus
07/24
08/24
WILLOW LTE, NCT05540327 / 2022-000239-21: The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE

Recruiting
2
532
Europe, Japan, US, RoW
M5049 low dose, Enpatoran, M5049 medium dose, M5049 high dose, Placebo, M5049 very high dose
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Merck Healthcare KGaA
Systemic Lupus Erythematosus
04/25
04/25
MARS-17, NCT05838742: A Dose-Finding Study to Evaluate the Efficacy and Safety of GSK3858279 in Adults With Knee Osteoarthritis Pain

Recruiting
2
420
Europe, Canada, Japan, US, RoW
GSK3858279, Placebo
GlaxoSmithKline
Pain
07/25
10/25
Oparanov, Boycho
TOPAZ-1, NCT04895241 / 2020-005775-12: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Checkmark Trial initiation of TOPAZ-1 trial in lupus
Jun 2021 - Jun 2021: Trial initiation of TOPAZ-1 trial in lupus
Recruiting
3
540
Europe, US, RoW
Litifilimab, BIIB059, Placebo
Biogen
Lupus Erythematosus, Systemic
03/25
09/25
NCT05531565 / 2020-000727-40: A Study to Assess the Efficacy and Safety of BIIB059 (Litifilimab) in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy

Recruiting
2/3
474
Europe, Canada, Japan, US, RoW
BIIB059 (litifilimab), litifilimab, Placebo
Biogen, Biogen Idec Research Limited
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
10/26
12/27
WILLOW, NCT05162586 / 2021-004648-27: The Study With M5049 in SLE and CLE (SCLE and/or DLE)

Active, not recruiting
2
532
Europe, Japan, US, RoW
Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Systemic Lupus Erythematosus
07/24
08/24
WILLOW LTE, NCT05540327 / 2022-000239-21: The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE

Recruiting
2
532
Europe, Japan, US, RoW
M5049 low dose, Enpatoran, M5049 medium dose, M5049 high dose, Placebo, M5049 very high dose
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Merck Healthcare KGaA
Systemic Lupus Erythematosus
04/25
04/25

Download Options